news
AI targets protein linked to most human cancers
Scientists have used AI to design a molecule that disrupts a key protein interaction driving up to 70 percent of cancers - once thought impossible to drug.
List view / Grid view
Oncology
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
article
Strategic planning in ADC development: insights from Lonza
Preclinical and clinical development are critical to the success of ADCs, where early strategic decisions regarding manufacturability and scalability can make or break a project. Iwan Bertholjotti of Lonza emphasises the importance of proactive planning to avoid costly delays and ensure smooth progress towards clinical success.
article
Transforming cancer care through clinical excellence
Melika Davis at BeOne reflects on the inspiration and drive that has helped her forge a successful career in clinical operations.
news
K Navigator: an AI co-pilot transforming biomedical research
K Navigator, a new AI-powered research co-pilot, is set to transform biomedical science by helping researchers explore complex data and accelerate discoveries.
news
Targeting the clock: new drug disrupts glioblastoma stem cells
Scientists have developed a new drug, SHP1705, that targets hijacked circadian clock proteins used by glioblastoma stem cells to grow and resist treatment.
news
New data: Visugromab targets ADC resistance mechanism
CatalYm announces new preclinical data showing that its clinical-stage antibody, visugromab, can overcome resistance to antibody-drug conjugates (ADCs), showing potential to restore anti-tumour immune responses in solid tumours.
news
Enedra secures funding to advance AI-driven cancer platform
Enedra Therapeutics has secured new funding to advance its AI-driven CASPAROV platform, aimed at developing therapies for difficult-to-treat cancers
article
AACR 2025: translating research into real-world impact
From first-in-human trial results to emerging AI tools and patient-focused innovations, AACR 2025 offered a clear snapshot of where cancer research is heading. Drug Target Review was on the ground in Chicago to explore the clinical data, technologies, and conversations shaping cancer drug development.
news
New dual-targeting strategy shows promise in treating pancreatic cancer
Researchers at the University of Michigan have discovered a powerful combination therapy that eradicates pancreatic tumours in preclinical models, offering hope for new treatments against one of the most treatment-resistant cancers.
news
Advanced test predicts ALK inhibitor success in lung cancer
Researchers have developed a test that accurately predicts whether patients with ALK-positive lung cancer will respond to targeted treatments. This could significantly enhance personalised cancer therapies and overcome treatment resistance.
news
PSPC1 knockout slows AML in preclinical models
Scientists at UT Health San Antonio have identified PSPC1 in mouse models as a promising new drug target for acute myeloid leukaemia (AML), a deadly blood cancer with limited treatment options.
news
New melanoma therapy prevents brain metastasis in preclinical studies
A government-funded research team has identified focal adhesion kinase (FAK) as a key driver of melanoma metastasis to the brain. This discovery could revolutionise treatment by not only addressing the condition but also preventing its spread to the brain.
news
Tract Bio identifies drug targets for oesophageal cancer
Tract Bio’s new research reveals key insights into the evolution of oesophageal adenocarcinoma (EAC) and identifies promising drug combinations for more effective treatment.
article
Why DNA Damage Response deserves renewed focus in cancer therapy
As cancer therapies evolve, a critical opportunity is emerging in the form of DNA Damage Response (DDR) research. With breakthroughs in genomics, drug delivery and AI, DDR pathways are set to overcome resistance and alter treatment strategies. Find out why now is the perfect moment to refocus on DDR, and…
news
Novel radioactive drug targets aggressive metastatic melanoma
Scientists in Japan have developed a new radioactive drug that emits alpha particles, showing promise for targeting metastatic melanoma - an aggressive skin cancer resistant to many conventional treatments.
